A Phase 3 interventional study of acoramidis and Placebo Oral Tablet in Amyloidosis, Amyloid Cardiomyopathy and Transthyretin Amyloidosis, sponsored by Eidos Therapeutics, a BridgeBio company. Completed at 104 sites in 18 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-06-27.
Sponsored by Eidos Therapeutics, a BridgeBio company (part of BridgeBio) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States — 10 open to participants now, 12 under way, 4 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · United States.
Among the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States, this one is the 4th largest by enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2019, is one of 10 in phase 3, and was the 9th registered.
82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.
Browse Amyloidosis, Hereditary, Transthyretin-Related studies →10 of the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Canada, China and 3 more countries
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in United States
Ages 18–80
Eidos Therapeutics, a BridgeBio company · Sites in United States, Argentina, Australia and 21 more countries
Ages 18–75
AstraZeneca · Sites in United States, Canada, China and 3 more countries
Ages 18–130
Intellia Therapeutics · Sites in United States, Argentina, Australia and 23 more countries
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 10 · Phase 4 3
First in 2008; this study’s year is marked. 7 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 632 is above the median of 80 across 36 interventional studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.
Median enrollment 150 across the 23 interventional studies, 119 across the 14 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 37 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eidos Therapeutics, a BridgeBio company, one of the names counted as BridgeBio. Under that name alone:
Eidos Therapeutics, a BridgeBio company is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
BridgeBio has 6 studies filed under Amyloidosis, Hereditary, Transthyretin-Related — fewer than ten, so there is no comparison to draw.
2 of the studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05489523University of Texas Southwestern Medical CenterSafety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation | 2027-05-31 |
| NCT05489549University of Texas Southwestern Medical CenterSubclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase 3 efficacy and safety study to evaluate acoramidis (AG10) HCl 800 mg administered orally twice a day compared to placebo in subjects with symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed condition believed to affect more than 400,000 people worldwide. In ATTR-CM, the accumulation of transthyretin (TTR) amyloid results in thickening and stiffening of the heart, which often leads to heart failure or even death.
There are two forms of ATTR-CM:
In this study we are researching the investigational drug acoramidis HCl 800 mg administered orally twice a day. Through the study, we want to evaluate the efficacy and safety of acoramidis in patients with ATTR-CM versus placebo.
This is a 30 month, randomized, double-blind, placebo-controlled study. This means that, during the 30 month study, investigators conducting the research and study participants will not know whether the study participant is receiving acoramidis or placebo.
The primary outcomes of the study are:
At the end of 30 months, participants may be eligible to receive investigational acoramidis, and there is no placebo. This is called an "open label extension." This separate study may help us better understand the safety related to taking acoramidis over a longer period of time.
82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.
This study's enrollment of 632 is above the median of 80 across 36 interventional studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.
Browse Amyloidosis, Hereditary, Transthyretin-Related studies →Eidos Therapeutics, a BridgeBio company is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
First submitted after Eidos Therapeutics became part of BridgeBio.
Compared within Amyloidosis, Hereditary, Transthyretin-Related, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Amyloidosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive acoramidis HCl 800 mg twice daily. 6MWT primary outcome will be assessed at the end of 12 months. The hierarchical combination of All-Cause mortality, cumulative frequency of cardiovascular-related hospitalizations, change from baseline in NT-proBNP levels, and change from baseline in distance walked on the 6MWT will be assessed after 30 months of treatment.
Drug: acoramidis
Subjects will receive placebo to match twice daily. 6MWT primary outcome will be assessed at the end of 12 months. The hierarchical combination of All-Cause mortality, cumulative frequency of cardiovascular-related hospitalizations, change from baseline in NT-proBNP levels, and change from baseline in distance walked on the 6MWT will be assessed after 30 months of treatment.
Drug: Placebo Oral Tablet
TTR stabilizer administered orally twice daily (BID)
Also known as: AG10, ALXN2060
Non-active control administered orally twice daily (BID)
A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments.
The endpoint was analyzed using Finkelstein-Schoenfeld method. The method combines all-cause mortality, cumulative frequency of CV-related hospitalizations, change from baseline in NT-proBNP and change from baseline in 6MWT in a hierarchical fashion. The method compares every participant with every other participant within strata, assigning a +1 to the "better" participant and a -1 to the "worse" participant and 0 if they are "tied". Participants who had heart transplantation or implantation of a cardiac mechanical assist device were handled in the same manner as death. 'Win' represents a participant doing better based on hierarchical comparison. The reported unit is the total percent of "wins" for each treatment group from performing such a hierarchical comparison across stratification factors in the study.
Time frame: Baseline up to Month 30
Change From Baseline to Month 30 in the Distance Walked During the 6 Minute Walk Test (6MWT)
6MWT measures the total distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.
Time frame: Month 30
Change From Baseline to Month 30 of the Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)
KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). The summary score of Overall Summary (calculated as mean of Physical limitation, Social limitation, Total symptoms, and Quality of life scores) was calculated. Domain and summary scores were scaled to range from 0 (minimum) to 100 (maximum); higher scores represent better health status.
Time frame: Month 30
Change From Baseline to Month 30 in Serum TTR (Prealbumin) Level
Serum TTR (Prealbumin) is an in vivo biomarker of stabilization.
Time frame: Month 30
All-cause Mortality by Month 30, Including Death Due to Any Cause, Heart Transplant or Cardiac Mechanical Assist Device (CMAD)
Number of deaths due to any cause was analyzed. Participants who had heart transplantation or implantation of a CMAD were handled in the same manner as death.
Time frame: Baseline up to Month 30
| Milestone | Acoramidis HCl 800 mg | Placebo |
|---|---|---|
| Started | 421 | 211 |
| Completed | 331 | 154 |
| Not completed | 90 | 57 |
| Withdrew: Withdrawal of consent | 15 | 6 |
| Withdrew: Death | 75 | 51 |
The endpoint was analyzed using Finkelstein-Schoenfeld method. The method combines all-cause mortality, cumulative frequency of CV-related hospitalizations, change from baseline in NT-proBNP and change from baseline in 6MWT in a hierarchical fashion. The method compares every participant with every other participant within strata, assigning a +1 to the "better" participant and a -1 to the "worse" participant and 0 if they are "tied". Participants who had heart transplantation or implantation of a cardiac mechanical assist device were handled in the same manner as death. 'Win' represents a participant doing better based on hierarchical comparison. The reported unit is the total percent of "wins" for each treatment group from performing such a hierarchical comparison across stratification factors in the study.
| Percent of Wins from Win Ratio | Acoramidis HCl 800 mg | Placebo |
|---|---|---|
| A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments. | 63.7 | 35.9 |
6MWT measures the total distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.
| Meter | Acoramidis HCl 800 mg | Placebo |
|---|---|---|
| Change From Baseline to Month 30 in the Distance Walked During the 6 Minute Walk Test (6MWT) | -64.65 ± 5.508 | -104.29 ± 7.772 |
KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). The summary score of Overall Summary (calculated as mean of Physical limitation, Social limitation, Total symptoms, and Quality of life scores) was calculated. Domain and summary scores were scaled to range from 0 (minimum) to 100 (maximum); higher scores represent better health status.
| Score on a scale | Acoramidis HCl 800 mg | Placebo |
|---|---|---|
| Change From Baseline to Month 30 of the Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) | -11.48 ± 1.181 | -21.42 ± 1.651 |
Serum TTR (Prealbumin) is an in vivo biomarker of stabilization.
| mg/dL | Acoramidis HCl 800 mg | Placebo |
|---|---|---|
| Change From Baseline to Month 30 in Serum TTR (Prealbumin) Level | 5.78 ± 0.391 | -1.32 ± 0.541 |
Number of deaths due to any cause was analyzed. Participants who had heart transplantation or implantation of a CMAD were handled in the same manner as death.
| Participants | Acoramidis HCl 800 mg | Placebo |
|---|---|---|
| All-cause Mortality by Month 30, Including Death Due to Any Cause, Heart Transplant or Cardiac Mechanical Assist Device (CMAD) | 79 | 52 |
Collected over In Study AG10-301 participants, treatment emergent adverse events (TEAEs) are defined as (a) events with onset after the first dose of study drug, or (b) if the event was present before the first dose of study drug, but increased in severity after the first dose of study drug, and (c) with onset date or severity increase date <= 30 days after the last dose of study drug (through AG10-301 Study completion, 30 months) or until the first dose in open label extension Study AG10-304.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acoramidis HCl 800 mg | 84/421 (20%) | 230/421 (54.6%) | 410/421 (97.4%) |
| Placebo | 55/211 (26.1%) | 137/211 (64.9%) | 199/211 (94.3%) |
| Event | Acoramidis HCl 800 mg | Placebo |
|---|---|---|
| Cardiac failureCardiac disorders | 45/421 | 39/211 |
| Atrial fibrillationCardiac disorders | 19/421 | 15/211 |
| Cardiac failure acuteCardiac disorders | 21/421 | 14/211 |
| Acute kidney injuryRenal and urinary disorders | 21/421 | 8/211 |
| COVID-19 pneumoniaInfections and infestations | 2/421 | 8/211 |
| FallInjury, poisoning and procedural complications | 13/421 | 2/211 |
| PneumoniaInfections and infestations | 12/421 | 6/211 |
| BradycardiaCardiac disorders | 11/421 | 2/211 |
| Ventricular tachycardiaCardiac disorders | 6/421 | 5/211 |
| HypervolaemiaMetabolism and nutrition disorders | 3/421 | 5/211 |
| Event | Acoramidis HCl 800 mg | Placebo |
|---|---|---|
| Cardiac failureCardiac disorders | 69/421 | 61/211 |
| COVID-19Infections and infestations | 80/421 | 27/211 |
| FallInjury, poisoning and procedural complications | 59/421 | 38/211 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 51/421 | 37/211 |
| Atrial fibrillationCardiac disorders | 55/421 | 36/211 |
| ConstipationGastrointestinal disorders | 51/421 | 31/211 |
| Urinary tract infectionInfections and infestations | 46/421 | 26/211 |
| FatigueGeneral disorders | 42/421 | 26/211 |
| Oedema peripheralGeneral disorders | 33/421 | 25/211 |
| DiarrhoeaGastrointestinal disorders | 48/421 | 16/211 |
Safety Population
| Age, Categorical(Participants) | Acoramidis HCl 800 mg | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 9 | 21 |
| >=65 years | 409 | 202 | 611 |
| Age, Continuous(years) | Acoramidis HCl 800 mg | Placebo | Total |
|---|---|---|---|
| Mean | 77.37 ± 6.450 | 77.09 ± 6.763 | 77.27 ± 6.552 |
| Sex: Female, Male(Participants) | Acoramidis HCl 800 mg | Placebo | Total |
|---|---|---|---|
| Female | 37 | 25 | 62 |
| Male | 384 | 186 | 570 |
| Ethnicity (NIH/OMB)(Participants) | Acoramidis HCl 800 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 4 | 12 |
| Not Hispanic or Latino | 401 | 199 | 600 |
| Unknown or Not Reported | 12 | 8 | 20 |
| Race (NIH/OMB)(Participants) | Acoramidis HCl 800 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 10 | 3 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 20 | 10 | 30 |
| White | 368 | 187 | 555 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 21 | 9 | 30 |
| Distance Walked During the 6 Minute Walk Test (6MWT)(Meter) | Acoramidis HCl 800 mg | Placebo | Total |
|---|---|---|---|
| Mean | 361.21 ± 103.705 | 348.37 ± 93.564 | 356.91 ± 100.531 |
| Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)(units on a scale) | Acoramidis HCl 800 mg | Placebo | Total |
|---|---|---|---|
| Mean | 71.52 ± 19.387 | 70.31 ± 20.541 | 71.12 ± 19.773 |
| Serum TTR (Prealbumin) Level(mg/dL) | Acoramidis HCl 800 mg | Placebo | Total |
|---|---|---|---|
| Mean | 23.16 ± 5.643 | 23.63 ± 6.070 | 23.32 ± 5.788 |
Showing the first 100 of 104 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2019 to primary completion in May 2023, 49 months.
Results were first posted in Jun 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acoramidis
Amyloidosis, Hereditary, Transthyretin-Related →
Eidos Therapeutics, a BridgeBio company →